Joel Reiss sold $4.3M of TDG
Co-Chief Operating Officer at TransDigm Group INC. 3,000 shares at an average of $1,424.27, traded Jun 20, 2025, filed Jun 20, 2025.
Score components
- +20RoleCOO
- +25Trade size$4.3M at market
- +10Share of holdings soldSold 45% of holdings
- +15Cluster4 insiders selling within 14 days
- -15Exercise and sellShares came from an option exercise in the same filing
- -2010b5-1 planPre-scheduled under a 10b5-1 plan
What happened after comparable sells
Same side and tier, against the S&P 500, at 1, 3 and 6 months. Shown to Pro users; the whole table is on the backtest page.
This signal so far: 1m +10.7%, 3m -5.0%, 6m -5.4%.
Price around the trade, and since
From a quarter before the trade to today. The arrow is the trade, the circle the day the filing reached EDGAR, which is the first day anyone outside could act; the dotted line is the S&P 500 rebased to that day's close.
Daily candles, adjusted for splits and dividends. Green arrows are insider buys, red are sells, sized by value; the dashed line is the close on the filing day, the dotted line SPY rebased to it.Charts by TradingView Lightweight Charts™
Rows in this filing
Every transaction in Form 4 0000950170-25-088583, as filed. Open on EDGAR
| Date | Transaction | Shares | Price | Value | Holdings after | Filed |
|---|---|---|---|---|---|---|
| Jun 20, 2025 | MOption exercise Common Stock10b5-1 | +3,000 | $284.97 | $855k | 6,600 | Jun 20, 2025 |
| Jun 20, 2025 | SOpen-market sale Common Stock10b5-1 | -200 | $1,410.11 | $282k | 6,400 | Jun 20, 2025 |
| Jun 20, 2025 | SOpen-market sale Common Stock10b5-1 | -100 | $1,411.86 | $141k | 6,300 | Jun 20, 2025 |
| Jun 20, 2025 | SOpen-market sale Common Stock10b5-1 | -356 | $1,420.70 | $506k | 5,944 | Jun 20, 2025 |
| Jun 20, 2025 | SOpen-market sale Common Stock10b5-1 | -154 | $1,421.49 | $219k | 5,790 | Jun 20, 2025 |
| Jun 20, 2025 | SOpen-market sale Common Stock10b5-1 | -254 | $1,422.52 | $361k | 5,536 | Jun 20, 2025 |
| Jun 20, 2025 | SOpen-market sale Common Stock10b5-1 | -447 | $1,424.40 | $637k | 5,089 | Jun 20, 2025 |
| Jun 20, 2025 | SOpen-market sale Common Stock10b5-1 | -233 | $1,425.22 | $332k | 4,856 | Jun 20, 2025 |
| Jun 20, 2025 | SOpen-market sale Common Stock10b5-1 | -495 | $1,426.79 | $706k | 4,361 | Jun 20, 2025 |
| Jun 20, 2025 | SOpen-market sale Common Stock10b5-1 | -10 | $1,427.72 | $14k | 4,351 | Jun 20, 2025 |
| Jun 20, 2025 | SOpen-market sale Common Stock10b5-1 | -451 | $1,430.03 | $645k | 3,900 | Jun 20, 2025 |
| Jun 20, 2025 | SOpen-market sale Common Stock10b5-1 | -300 | $1,431.11 | $429k | 3,600 | Jun 20, 2025 |
| Jun 20, 2025 | MOption exercise Stock Optionderivative10b5-1 | -3,000 | $0.00 | $0 | 59,000 | Jun 20, 2025 |
Related signals
Other insiders at TransDigm Group INC and this insider’s other filings.
| Score | Company | Insider | Value | Holdings | Filed |
|---|---|---|---|---|---|
| 30Weak | TransDigm Group INC | Joel Reiss Co-Chief Operating Officer | $4.3M 3,900 shares | -52% | |
| 23Weak | TransDigm Group INC | W Nicholas Howley director | $13M 10,132 shares | -32% | |
| 38Weak | TransDigm Group INC | Joel Reiss Co-Chief Operating Officer | $4.8M 3,900 shares | -52% | |
| 23Weak | TransDigm Group INC | W Nicholas Howley director | $12M 10,132 shares | -32% | |
| 28Weak | TransDigm Group INC | Joel Reiss Co-Chief Operating Officer | $4.2M 3,486 shares | -46% | |
| 31Weak | TransDigm Group INC | Joel Reiss Co-Chief Operating Officer | $510k 414 shares | -10% | |
| 43Moderate | TransDigm Group INC | W Nicholas Howley director | $13M 10,132 shares | -32% | |
| 43Moderate | TransDigm Group INC | W Nicholas Howley director | $13M 10,132 shares | -32% | |
| 43Moderate | TransDigm Group INC | W Nicholas Howley director | $13M 10,132 shares | -32% | |
| 58Moderate | TransDigm Group INC | Joel Reiss Co-Chief Operating Officer | $5.0M 3,900 shares | -52% |
Not investment advice. Scores and forward returns are decision support built from public SEC filings and past prices; they describe what happened after comparable filings, not what will happen after this one. Do your own research and size your risk.